Uniphar (UPR) Competitors

In the previous week, Hikma Pharmaceuticals had 3 more articles in the media than Uniphar. MarketBeat recorded 4 mentions for Hikma Pharmaceuticals and 1 mentions for Uniphar. Uniphar's average media sentiment score of 0.54 beat Hikma Pharmaceuticals' score of 0.31 indicating that Uniphar is being referred to more favorably in the news media.

Hikma Pharmaceuticals has higher revenue and earnings than Uniphar. Hikma Pharmaceuticals is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Hikma Pharmaceuticals currently has a consensus target price of GBX 2,128, indicating a potential upside of 50.83%. Uniphar has a consensus target price of GBX 427.50, indicating a potential upside of 20.63%. Given Hikma Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts plainly believe Hikma Pharmaceuticals is more favorable than Uniphar.

Hikma Pharmaceuticals pays an annual dividend of GBX 84.14 per share and has a dividend yield of 6.0%. Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.6%. Hikma Pharmaceuticals pays out 46.5% of its earnings in the form of a dividend. Uniphar pays out 10.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Hikma Pharmaceuticals has a beta of 0.614, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Uniphar has a beta of 1.142, suggesting that its share price is 14% more volatile than the S&P 500.

Hikma Pharmaceuticals has a net margin of 12.00% compared to Uniphar's net margin of 1.66%. Hikma Pharmaceuticals' return on equity of 15.83% beat Uniphar's return on equity.

63.6% of Hikma Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.3% of Uniphar shares are owned by institutional investors. 18.2% of Hikma Pharmaceuticals shares are owned by insiders. Comparatively, 7.6% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Uniphar had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Uniphar and 0 mentions for Abcam. Uniphar's average media sentiment score of 0.54 beat Abcam's score of 0.00 indicating that Uniphar is being referred to more favorably in the media.

Uniphar has higher revenue and earnings than Abcam. Abcam is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Uniphar currently has a consensus target price of GBX 427.50, indicating a potential upside of 20.63%. Given Uniphar's stronger consensus rating and higher possible upside, research analysts plainly believe Uniphar is more favorable than Abcam.

Uniphar has a net margin of 1.66% compared to Abcam's net margin of 0.00%. Uniphar's return on equity of 13.14% beat Abcam's return on equity.

35.3% of Uniphar shares are owned by institutional investors. 7.6% of Uniphar shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Indivior had 4 more articles in the media than Uniphar. MarketBeat recorded 5 mentions for Indivior and 1 mentions for Uniphar. Uniphar's average media sentiment score of 0.54 beat Indivior's score of 0.00 indicating that Uniphar is being referred to more favorably in the media.

35.3% of Uniphar shares are held by institutional investors. Comparatively, 86.0% of Indivior shares are held by institutional investors. 7.6% of Uniphar shares are held by insiders. Comparatively, 3.4% of Indivior shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Uniphar has higher revenue and earnings than Indivior. Indivior is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Uniphar has a beta of 1.142, meaning that its stock price is 14% more volatile than the S&P 500. Comparatively, Indivior has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

Uniphar currently has a consensus target price of GBX 427.50, indicating a potential upside of 20.63%. Given Uniphar's stronger consensus rating and higher probable upside, analysts clearly believe Uniphar is more favorable than Indivior.

Indivior has a net margin of 14.30% compared to Uniphar's net margin of 1.66%. Uniphar's return on equity of 13.14% beat Indivior's return on equity.

Uniphar pays an annual dividend of GBX 1.96 per share and has a dividend yield of 0.6%. Indivior pays an annual dividend of GBX 15 per share and has a dividend yield of 1.2%. Uniphar pays out 10.1% of its earnings in the form of a dividend. Indivior pays out -1,243.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Indivior is clearly the better dividend stock, given its higher yield and lower payout ratio.

In the previous week, Uniphar and Uniphar both had 1 articles in the media. HUTCHMED's average media sentiment score of 0.58 beat Uniphar's score of 0.54 indicating that HUTCHMED is being referred to more favorably in the news media.

35.3% of Uniphar shares are owned by institutional investors. Comparatively, 20.7% of HUTCHMED shares are owned by institutional investors. 7.6% of Uniphar shares are owned by insiders. Comparatively, 2.8% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Uniphar has higher revenue and earnings than HUTCHMED. HUTCHMED is trading at a lower price-to-earnings ratio than Uniphar, indicating that it is currently the more affordable of the two stocks.

Uniphar has a beta of 1.142, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, HUTCHMED has a beta of 0.453, indicating that its stock price is 55% less volatile than the S&P 500.

Uniphar currently has a consensus target price of GBX 427.50, indicating a potential upside of 20.63%. Given Uniphar's stronger consensus rating and higher probable upside, analysts clearly believe Uniphar is more favorable than HUTCHMED.

HUTCHMED has a net margin of 104.77% compared to Uniphar's net margin of 1.66%. HUTCHMED's return on equity of 41.38% beat Uniphar's return on equity.